Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov
Format: Article
Language:Russian
Published: IRBIS LLC 2019-01-01
Series:Фармакоэкономика
Subjects:
prostate cancer
enzalutamide
abiraterone
pharmacoeconomic evaluation
public spending
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/268
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items